These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma. Storm PB; Renard VM; Moriarity JL; Tyler B; Wilentz RE; Brem H; Weingart JD Cancer Chemother Pharmacol; 2004 Oct; 54(4):361-7. PubMed ID: 15197484 [TBL] [Abstract][Full Text] [Related]
3. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo. Pollack IF; Erff M; Bom D; Burke TG; Strode JT; Curran DP Cancer Res; 1999 Oct; 59(19):4898-905. PubMed ID: 10519402 [TBL] [Abstract][Full Text] [Related]
4. Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient. Adams DJ; Wahl ML; Flowers JL; Sen B; Colvin M; Dewhirst MW; Manikumar G; Wani MC Cancer Chemother Pharmacol; 2006 Jan; 57(2):145-54. PubMed ID: 16001167 [TBL] [Abstract][Full Text] [Related]
5. Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts. Castellino RC; Elion GB; Keir ST; Houghton PJ; Johnson SP; Bigner DD; Friedman HS Cancer Chemother Pharmacol; 2000; 45(4):345-9. PubMed ID: 10755324 [TBL] [Abstract][Full Text] [Related]
6. Camptothecin analogues with enhanced antitumor activity at acidic pH. Adams DJ; Dewhirst MW; Flowers JL; Gamcsik MP; Colvin OM; Manikumar G; Wani MC; Wall ME Cancer Chemother Pharmacol; 2000; 46(4):263-71. PubMed ID: 11052623 [TBL] [Abstract][Full Text] [Related]
7. Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells. Jones CB; Clements MK; Wasi S; Daoud SS Cancer Chemother Pharmacol; 1997; 40(6):475-83. PubMed ID: 9332461 [TBL] [Abstract][Full Text] [Related]
8. Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Coggins CA; Elion GB; Houghton PJ; Hare CB; Keir S; Colvin OM; Bigner DD; Friedman HS Cancer Chemother Pharmacol; 1998; 41(6):485-90. PubMed ID: 9554593 [TBL] [Abstract][Full Text] [Related]
9. The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. Friedman HS; Keir ST; Houghton PJ Cancer; 2003 May; 97(9 Suppl):2359-62. PubMed ID: 12712457 [TBL] [Abstract][Full Text] [Related]
10. [Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11]. Matsumoto Y; Fujiwara T; Honjo Y; Sasaoka N; Tsuchida T; Nagao S Noshuyo Byori; 1994; 11(1):59-64. PubMed ID: 8162152 [TBL] [Abstract][Full Text] [Related]
11. Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11. Matsumoto Y; Fujiwara T; Honjo Y; Sasaoka N; Tsuchida T; Nagao S J Surg Oncol; 1993 Jun; 53(2):97-103. PubMed ID: 8388965 [TBL] [Abstract][Full Text] [Related]
12. DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors. Kuo CC; Liu JF; Chang JY J Pharmacol Exp Ther; 2006 Feb; 316(2):946-54. PubMed ID: 16258022 [TBL] [Abstract][Full Text] [Related]
13. Novel 7-alkyl methylenedioxy-camptothecin derivatives exhibit increased cytotoxicity and induce persistent cleavable complexes both with purified mammalian topoisomerase I and in human colon carcinoma SW620 cells. Valenti M; Nieves-Neira W; Kohlhagen G; Kohn KW; Wall ME; Wani MC; Pommier Y Mol Pharmacol; 1997 Jul; 52(1):82-7. PubMed ID: 9224816 [TBL] [Abstract][Full Text] [Related]
14. Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo. Laboratory investigation. Wang W; Ghandi A; Liebes L; Louie SG; Hofman FM; Schönthal AH; Chen TC J Neurosurg; 2011 Mar; 114(3):689-94. PubMed ID: 20415520 [TBL] [Abstract][Full Text] [Related]
15. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin. Chang JY; Liu JF; Juang SH; Liu TW; Chen LT Cancer Res; 2002 Jul; 62(13):3716-21. PubMed ID: 12097280 [TBL] [Abstract][Full Text] [Related]
16. Pre-clinical evaluation of SN-38 and novel camptothecin analogs against human chronic B-cell lymphocytic leukemia lymphocytes. Cohen DP; Adams DJ; Flowers JL; Wall ME; Wani MC; Manikumar G; Colvin OM; Silber R Leuk Res; 1999 Nov; 23(11):1061-70. PubMed ID: 10576512 [TBL] [Abstract][Full Text] [Related]
17. Hydrophilic camptothecin analogs that form extremely stable cleavable complexes with DNA and topoisomerase I. Wadkins RM; Bearss D; Manikumar G; Wani MC; Wall ME; Von Hoff DD Cancer Res; 2004 Sep; 64(18):6679-83. PubMed ID: 15374984 [TBL] [Abstract][Full Text] [Related]
18. Camptothecin analogs with enhanced activity against human breast cancer cells. I. Correlation of potency with lipophilicity and persistence in the cleavage complex. Adams DJ; da Silva MW; Flowers JL; Kohlhagen G; Pommier Y; Colvin OM; Manikumar G; Wani MC Cancer Chemother Pharmacol; 2006 Jan; 57(2):135-44. PubMed ID: 16151810 [TBL] [Abstract][Full Text] [Related]
19. Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma. Chen TC; Su S; Fry D; Liebes L Cancer; 2003 May; 97(9 Suppl):2363-73. PubMed ID: 12712458 [TBL] [Abstract][Full Text] [Related]
20. Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines. Janss AJ; Cnaan A; Zhao H; Shpilsky A; Levow C; Sutton L; Phillips PC Anticancer Drugs; 1998 Aug; 9(7):641-52. PubMed ID: 9773809 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]